In the non-approvable letter, the FDA has requested safety data from additional clinical studies to address concerns over the safety of Injectafer in this population, specifically the mortality signal.
Mary Jane Helenek, president and CEO, said: “While we are disappointed about this latest decision, we are committed to the further development of Injectafer and are working on new studies in support of our application and to address the FDA’s concerns.”